{"schema":"hottub-news/story/v1","story":"st_szp2xjwbeo7ricccmnlq","title":"Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes","title_en":null,"outlets":8,"brief":null,"page":"https://hottub.news/stories/boehringer-ingelheims-survodutide-achieves-up-to-13-1-weight-loss-in-szp2xjwbeo","count":8,"items":[{"id":"n_3pcdykhnkmm5sb3lhu7a","seq":1266854,"kind":"article","title":"Experimental Survodutide Cut Weight Up to 13.1% in Adults with Type 2 Diabetes in Boehringer's Phase 3 Trial","url":"https://www.medicaldaily.com/survodutide-phase-3-type-2-diabetes-weight-loss-nejm-479379","summary":"Survodutide cut weight by up to 13.1% in adults with type 2 diabetes in a company-funded trial. It is not approved, and 18% quit due to side effects.","published":"2026-10-02T02:38:54Z","seen":"2026-10-02T04:54:28Z","lang":"en","source":{"id":"kite-medicaldaily-com-05fda3","name":"medicaldaily.com","domain":"medicaldaily.com","outlet":{"wikidata":"Q69052919","name":"Medical Daily","type":"website","country":"US","designations":["website"]}},"via":"kite-medicaldaily-com-05fda3","topics":["medicine"],"entities":[{"id":"Q1248127","name":"Boehringer","type":"org"}],"story":"st_szp2xjwbeo7ricccmnlq","category":"health","category_p":0.800000011920929,"sentiment":"positive","tone":0.27000001072883606,"political":0.019999999552965164},{"id":"n_odd5oew2qtpjmn3pkv4a","seq":1089015,"kind":"article","title":"Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes","url":"https://www.finanznachrichten.de/nachrichten-2026-10/69726969-zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvement-399.htm","published":"2026-10-01T08:33:23Z","seen":"2026-10-01T08:33:23Z","lang":"en","country":"DE","source":{"id":"finanznachrichten.de","name":"finanznachrichten.de","domain":"finanznachrichten.de","outlet":{"wikidata":"Q1408247","name":"Finanznachrichten.de","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","business","health","politics"],"authors":["GlobeNewswire (Europe)"],"entities":[{"id":"Q18552286","name":"Zealand Pharma","type":"org"},{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"},{"id":"Q123907235","name":"survodutide","type":"other"}],"story":"st_szp2xjwbeo7ricccmnlq","category":"health","category_p":0.7599999904632568,"sentiment":"positive","tone":0.029999999329447746,"political":0.019999999552965164},{"id":"n_f4k4emu4x3ixa7bdgtca","seq":1087516,"kind":"article","title":"Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes","url":"https://www.chathamdailynews.ca/press-releases/globe-newswire/boehringer-ingelheims-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-diabetes","published":"2026-10-01T07:33:00Z","seen":"2026-10-01T08:32:12Z","lang":"en","country":"CA","source":{"id":"chathamdailynews.ca","name":"chathamdailynews.ca","domain":"chathamdailynews.ca","outlet":{"wikidata":"Q126490070","name":"The Chatham Daily News","type":"newspaper","designations":["local newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["GlobeNewswire"],"entities":[{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"},{"id":"Q123907235","name":"survodutide","type":"other"}],"story":"st_szp2xjwbeo7ricccmnlq","category":"health","category_p":0.7799999713897705,"sentiment":"positive","tone":0.12999999523162842,"political":0.009999999776482582},{"id":"n_bca6mxwtudmufmvokmya","seq":1087337,"kind":"article","title":"Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes","url":"https://www.recorder.ca/press-releases/globe-newswire/boehringer-ingelheims-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-diabetes","published":"2026-10-01T07:32:00Z","seen":"2026-10-01T08:32:12Z","lang":"en","country":"CA","source":{"id":"recorder.ca","name":"recorder.ca","domain":"recorder.ca"},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["GlobeNewswire"],"entities":[{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"}],"story":"st_szp2xjwbeo7ricccmnlq","category":"health","category_p":0.7799999713897705,"sentiment":"positive","tone":0.12999999523162842,"political":0.009999999776482582},{"id":"n_e5vasmq7nhcvfpiecruq","seq":1092180,"kind":"article","title":"Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes","url":"https://www.standard-freeholder.com/press-releases/globe-newswire/boehringer-ingelheims-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-diabetes","published":"2026-10-01T07:32:00Z","seen":"2026-10-01T08:39:23Z","lang":"en","source":{"id":"standard-freeholder.com","name":"standard-freeholder.com","domain":"standard-freeholder.com"},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["GlobeNewswire"],"entities":[{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"}],"story":"st_szp2xjwbeo7ricccmnlq","category":"health","category_p":0.7799999713897705,"sentiment":"positive","tone":0.12999999523162842,"political":0.009999999776482582},{"id":"n_5bd477y666vs2nd5kpla","seq":1098823,"kind":"article","title":"Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes","url":"https://www.intelligencer.ca/press-releases/globe-newswire/boehringer-ingelheims-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-diabetes","published":"2026-10-01T07:32:00Z","seen":"2026-10-01T09:31:02Z","lang":"en","country":"CA","source":{"id":"intelligencer.ca","name":"intelligencer.ca","domain":"intelligencer.ca","outlet":{"wikidata":"Q4883859","name":"Belleville Intelligencer","type":"magazine","country":"CA","designations":["periodical"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["GlobeNewswire"],"entities":[{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"},{"id":"Q123907235","name":"survodutide","type":"other"}],"story":"st_szp2xjwbeo7ricccmnlq","category":"health","category_p":0.7799999713897705,"sentiment":"positive","tone":0.12999999523162842,"political":0.009999999776482582},{"id":"n_p3tzxf4zj7upivtww2ka","seq":1079717,"kind":"press_release","title":"Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes","url":"https://www.globenewswire.com/news-release/2026/10/01/3372565/0/en/zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-.html","summary":"Company announcement – No. 52 / 2026","published":"2026-10-01T07:30:00Z","seen":"2026-10-01T07:52:04Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","copenhagen:zeal","dk0060257814","7716"],"entities":[{"id":"Q18552286","name":"Zealand Pharma","type":"org"},{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"},{"id":"Q123907235","name":"survodutide","type":"other"}],"mentions":2,"story":"st_szp2xjwbeo7ricccmnlq","category":"health","category_p":0.7699999809265137,"sentiment":"positive","tone":0.47999998927116394,"political":0.019999999552965164},{"id":"n_szp2xjwbeo7ricccmnlq","seq":1080483,"kind":"press_release","title":"Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes","url":"https://www.globenewswire.com/news-release/2026/10/01/3372564/0/en/boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-d.html","summary":"Ingelheim, Germany - Boehringer Ingelheim today announced positive results from the Phase III SYNCHRONIZE-2 trial, which investigates the glucagon/GLP-1 receptor dual agonist survodutide (BI 456906) in adults living with obesity or overweight and type 2 diabetes (T2D). 1 The trial met its co-primary endpoints, which were % change in body weight from baseline and body weight reduction of ≥5% from baseline, using both the treatment-regimen* and efficacy estimands † . 1 After…","published":"2026-10-01T07:30:00Z","seen":"2026-10-01T07:53:25Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"},{"id":"Q123907235","name":"survodutide","type":"other"}],"image":"https://ml-eu.globenewswire.com/Resource/Download/d5e21fe1-beec-4d8a-8d99-4b080026b68f","story":"st_szp2xjwbeo7ricccmnlq","category":"health","category_p":0.7799999713897705,"sentiment":"positive","tone":0.5199999809265137,"political":0.009999999776482582}]}